Skip to main content
SpringerLink
Log in
Book cover

Primary Liver Cancer pp 143–160Cite as

Hepatocellular Carcinoma in Children

  • Chapter
  • First Online:

  • 1465 Accesses

Part of the book series: Clinical Gastroenterology ((CG))

Abstract

Hepatocellular carcinoma (HCC) is the second most common malignant liver tumor in children after hepatoblastoma (HB) and accounts for approximately 0.3% of all pediatric malignancies [1]. The age-adjusted incidence rate of HCC in the United States in children is 0.41 (0.24–0.65) per 1,000,000 population, with no gender predominance [1]. Children with HCC may present at any age, although the incidence is highest between the ages of 10–19 years [1–3].

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

α1-AT:

Alpha-1-antitrypsin

AJCC:

American Joint Committee on Cancer

COG:

Children’s Oncology Group

FAP:

Familial adenomatous polyposis

FL-HCC:

Fibrolamellar HCC

GSD1:

Glycogen storage disease type 1

HB:

Hepatoblastoma

HCC:

Hepatocellular carcinoma

HBV:

Hepatitis B virus

HCV:

Hepatitis C virus

HT-1:

Hereditary tyrosinemia type 1

L3-AFP:

Lectin-reactive alpha-fetoprotein

OLT:

Orthotopic liver transplantation

PRETEXT:

Pretreatment extent of disease

PFIC:

Progressive familial intrahepatic cholestasis

SIOPEL:

Societé Internationale d’Oncologie Pédiatrique

References

  1. Darbari A, Sabin KM, Shapiro CN, Schwarz KB. Epidemiology of primary hepatic malignancies in U.S. children. Hepatology. 2003;38:560–6.

    Article  PubMed  Google Scholar 

  2. Laiq Z, Bishop JA, Ali SZ. Liver lesions in children and adolescents: Cytopathologic analysis and clinical correlates in 44 cases. Diagn Cytopathol 2011 Feb 9. doi:10.1002/dc.21587. [Epub ahead of print].

    Google Scholar 

  3. Meyers RL. Tumors of the liver in children. Surg Oncol. 2007;16:195–203.

    Article  PubMed  Google Scholar 

  4. Wu TC, Tong MJ, Hwang B, Lee SD, Hu MM. Primary hepatocellular carcinoma and hepatitis B infection during childhood. Hepatology. 1987;7:46–8.

    Article  PubMed  CAS  Google Scholar 

  5. Lanier AP, Holck P, Ehrsam DG, Key C. Childhood cancer among Alaska Natives. Pediatrics. 2003;112:e396.

    Article  PubMed  Google Scholar 

  6. Tajiri H, Tanaka H, Brooks S, Takano T. Reduction of hepatocellular carcinoma in childhood after introduction of selective vaccination against hepatitis B virus for infants born to HBV carrier mothers. Cancer Causes Control 2011;22(3):523–7.

    Google Scholar 

  7. Chang MH, Chen CJ, Lai MS, Hsu HM, Wu TC, Kong MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med. 1997;336:1855–9.

    Article  PubMed  CAS  Google Scholar 

  8. Chang MH, Shau WY, Chen CJ, Wu TC, Kong MS, Liang DC, et al. Hepatitis B vaccination and hepatocellular carcinoma rates in boys and girls. J Am Med Assoc. 2000;284:3040–2.

    Article  CAS  Google Scholar 

  9. Davison SM, Mieli-Vergani G, Sira J, Kelly DA. Perinatal hepatitis C virus infection: diagnosis and management. Arch Dis Child. 2006;91:781–5.

    Article  PubMed  CAS  Google Scholar 

  10. Mohan P, Colvin C, Glymph C, Chandra RR, Kleiner DE, Patel KM, et al. Clinical spectrum and histopathologic features of chronic hepatitis C infection in children. J Pediatr. 2007;150:168–74.

    Article  PubMed  Google Scholar 

  11. Strickland DK, Jenkins JJ, Hudson MM. Hepatitis C infection and hepatocellular carcinoma after treatment of childhood cancer. J Pediatr Hematol Oncol. 2001;23:527–9.

    Article  PubMed  CAS  Google Scholar 

  12. Castellino S, Lensing S, Riely C, Rai SN, Davila R, Hayden RT, et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children’s Research Hospital hepatitis C seropositive cohort. Blood. 2004;103:2460–6.

    Article  PubMed  CAS  Google Scholar 

  13. Weinberg AG, Mize CE, Worthen HG. The occurrence of hepatoma in the chronic form of hereditary tyrosinemia. J Pediatr. 1976;88:434–8.

    Article  PubMed  CAS  Google Scholar 

  14. van Spronsen FJ, Thomasse Y, Smit GP, Leonard JV, Clayton PT, Fidler V, et al. Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment. Hepatology. 1994;20:1187–91.

    Article  PubMed  Google Scholar 

  15. Masurel-Paulet A, Poggi-Bach J, Rolland MO, Bernard O, Guffon N, Dobbelaere D, et al. NTBC treatment in tyrosinaemia type I: long-term outcome in French patients. J Inherit Metab Dis. 2008;31:81–7.

    Article  PubMed  CAS  Google Scholar 

  16. van Spronsen FJ, Bijleveld CM, van Maldegem BT, Wijburg FA. Hepatocellular carcinoma in hereditary tyrosinemia type I despite 2-(2 nitro-4-3 trifluoro- methylbenzoyl)-1, 3-cyclohexanedione treatment. J Pediatr Gastroenterol Nutr. 2005;40:90–3.

    Article  PubMed  Google Scholar 

  17. Perlmutter DH. Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr Res. 2006;60:233–8.

    Article  PubMed  CAS  Google Scholar 

  18. Arnon R, Kerkar N, Davis MK, Anand R, Yin W, Gonzalez-Peralta RP. Liver transplantation in children with metabolic diseases: the studies of pediatric liver transplantation experience. Pediatr Transplant. 2010;14:796–805.

    Article  PubMed  Google Scholar 

  19. Carlson J, Eriksson S. Chronic ‘cryptogenic’ liver disease and malignant hepatoma in intermediate alpha 1-antitrypsin deficiency identified by a Pi Z-specific monoclonal antibody. Scand J Gastroenterol. 1985;20:835–42.

    Article  PubMed  CAS  Google Scholar 

  20. Zhou H, Fischer HP. Liver carcinoma in PiZ alpha-1-antitrypsin deficiency. Am J Surg Pathol. 1998;22:742–8.

    Article  PubMed  CAS  Google Scholar 

  21. Elzouki AN, Eriksson S. Risk of hepatobiliary disease in adults with severe alpha 1-antitrypsin deficiency (PiZZ): is chronic viral hepatitis B or C an additional risk factor for cirrhosis and hepatocellular carcinoma? Eur J Gastroenterol Hepatol. 1996;8:989–94.

    Article  PubMed  CAS  Google Scholar 

  22. Bhadri VA, Stormon MO, Arbuckle S, Lam AH, Gaskin KJ, Shun A. Hepatocellular carcinoma in children with Alagille syndrome. J Pediatr Gastroenterol Nutr. 2005;41:676–8.

    Article  PubMed  Google Scholar 

  23. Kaufman SS, Wood RP, Shaw Jr BW, Markin RS, Gridelli B, Vanderhoof JA. Hepatocarcinoma in a child with the Alagille syndrome. Am J Dis Child. 1987;141:698–700.

    PubMed  CAS  Google Scholar 

  24. McDaniell R, Warthen DM, Sanchez-Lara PA, Pai A, Krantz ID, Piccoli DA, et al. NOTCH2 mutations cause Alagille syndrome, a heterogeneous disorder of the notch signaling pathway. Am J Hum Genet. 2006;79:169–73.

    Article  PubMed  CAS  Google Scholar 

  25. Yao Z, Mishra L. Cancer stem cells and hepatocellular carcinoma. Cancer Biol Ther. 2009;8:1691–8.

    Article  PubMed  CAS  Google Scholar 

  26. Rake JP, Visser G, Labrune P, Leonard JV, Ullrich K, Smit GP. Glycogen storage disease type I: diagnosis, management, clinical course and outcome. Results of the European Study on Glycogen Storage Disease Type I (ESGSD I). Eur J Pediatr. 2002;161 Suppl 1:S20–34.

    PubMed  CAS  Google Scholar 

  27. Farges O, Dokmak S. Malignant transformation of liver adenoma: an analysis of the literature. Dig Surg. 2010;27:32–8.

    Article  PubMed  Google Scholar 

  28. Tward AD, Jones KD, Yant S, Cheung ST, Fan ST, Chen X, et al. Distinct pathways of genomic progression to benign and malignant tumors of the liver. Proc Natl Acad Sci USA. 2007;104:14771–6.

    Article  PubMed  CAS  Google Scholar 

  29. Franco LM, Krishnamurthy V, Bali D, Weinstein DA, Arn P, Clary B, et al. Hepatocellular carcinoma in glycogen storage disease type Ia: a case series. J Inherit Metab Dis. 2005;28:153–62.

    Article  PubMed  CAS  Google Scholar 

  30. Brunati A, Feruzi Z, Sokal E, Smets F, Fervaille C, Gosseye S, et al. Early occurrence of hepatocellular carcinoma in biliary atresia treated by liver transplantation. Pediatr Transplant. 2007;11:117–9.

    Article  PubMed  Google Scholar 

  31. Tatekawa Y, Asonuma K, Uemoto S, Inomata Y, Tanaka K. Liver transplantation for biliary atresia associated with malignant hepatic tumors. J Pediatr Surg. 2001;36:436–9.

    Article  PubMed  CAS  Google Scholar 

  32. Iida T, Zendejas IR, Kayler LK, Magliocca JF, Kim RD, Hemming AW, et al. Hepatocellular carcinoma in a 10-month-old biliary atresia child. Pediatr Transplant. 2009;13:1048–9.

    Article  PubMed  Google Scholar 

  33. Starzl TE, Giles G, Lilly JR, Takagi H, Martineau G, Schroter G, et al. Indications for orthotopic liver transplantation: with particular reference to hepatomas, biliary atresia, cirrhosis, Wilson’s disease and serum hepatitis. Transplant Proc. 1971;3:308–12.

    PubMed  CAS  Google Scholar 

  34. Strautnieks SS, Bull LN, Knisely AS, Kocoshis SA, Dahl N, Arnell H, et al. A gene encoding a liver-specific ABC transporter is mutated in progressive familial intrahepatic cholestasis. Nat Genet. 1998;20:233–8.

    Article  PubMed  CAS  Google Scholar 

  35. Knisely AS, Strautnieks SS, Meier Y, Stieger B, Byrne JA, Portmann BC, et al. Hepatocellular carcinoma in ten children under five years of age with bile salt export pump deficiency. Hepatology. 2006;44:478–86.

    Article  PubMed  CAS  Google Scholar 

  36. Bodmer WF, Bailey CJ, Bodmer J, Bussey HJ, Ellis A, Gorman P, et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature. 1987;328:614–6.

    Article  PubMed  CAS  Google Scholar 

  37. Giardiello FM, Offerhaus GJ, Krush AJ, Booker SV, Tersmette AC, Mulder JW, et al. Risk of hepatoblastoma in familial adenomatous polyposis. J Pediatr. 1991;119:766–8.

    Article  PubMed  CAS  Google Scholar 

  38. Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet. 1992;43:1023–5.

    Article  PubMed  CAS  Google Scholar 

  39. Su LK, Abdalla EK, Law CH, Kohlmann W, Rashid A, Vauthey JN. Biallelic inactivation of the APC gene is associated with hepatocellular carcinoma in familial adenomatous polyposis coli. Cancer. 2001;92:332–9.

    Article  PubMed  CAS  Google Scholar 

  40. Gruner BA, DeNapoli TS, Andrews W, Tomlinson G, Bowman L, Weitman SD. Hepatocellular carcinoma in children associated with Gardner syndrome or familial adenomatous polyposis. J Pediatr Hematol Oncol. 1998;20:274–8.

    Article  PubMed  CAS  Google Scholar 

  41. Thompson MD, Monga SP. WNT/beta-catenin signaling in liver health and disease. Hepatology. 2007;45:1298–305.

    Article  PubMed  CAS  Google Scholar 

  42. Sun Z, Lu P, Gail MH, Pee D, Zhang Q, Ming L, et al. Increased risk of hepatocellular carcinoma in male hepatitis B surface antigen carriers with chronic hepatitis who have detectable urinary aflatoxin metabolite M1. Hepatology. 1999;30:379–83.

    Article  PubMed  CAS  Google Scholar 

  43. Liu J, Waalkes MP. Liver is a target of arsenic carcinogenesis. Toxicol Sci. 2008;105:24–32.

    Article  PubMed  CAS  Google Scholar 

  44. Liaw J, Marshall G, Yuan Y, Ferreccio C, Steinmaus C, Smith AH. Increased childhood liver cancer mortality and arsenic in drinking water in northern Chile. Cancer Epidemiol Biomarkers Prev. 2008;17:1982–7.

    Article  PubMed  CAS  Google Scholar 

  45. Czauderna P. Adult type vs. Childhood hepatocellular carcinoma—are they the same or different lesions? Biology, natural history, prognosis, and treatment. Med Pediatr Oncol. 2002;39:519–23.

    Article  PubMed  CAS  Google Scholar 

  46. Di Bisceglie AM, Rustgi VK, Hoofnagle JH, Dusheiko GM, Lotze MT. NIH conference. Hepatocellular carcinoma. Ann Intern Med. 1988;108:390–401.

    PubMed  Google Scholar 

  47. Kew MC. Hepatocellular carcinoma with and without cirrhosis. A comparison in southern African blacks. Gastroenterology. 1989;97:136–9.

    PubMed  CAS  Google Scholar 

  48. Prokurat A, Kluge P, Kosciesza A, Perek D, Kappeler A, Zimmermann A. Transitional liver cell tumors (TLCT) in older children and adolescents: a novel group of aggressive hepatic tumors expressing beta-catenin. Med Pediatr Oncol. 2002;39:510–8.

    Article  PubMed  Google Scholar 

  49. Stocker JT, Husain AN, Dehner LP, Chandra RS. Pediatric pathology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 773.

    Google Scholar 

  50. Edmondson HA. Differential diagnosis of tumors and tumor-like lesions of liver in infancy and childhood. AMA J Dis Child. 1956;91:168–86.

    PubMed  CAS  Google Scholar 

  51. Berman MA, Burnham JA, Sheahan DG. Fibrolamellar carcinoma of the liver: an immunohistochemical study of nineteen cases and a review of the literature. Hum Pathol. 1988;19:784–94.

    Article  PubMed  CAS  Google Scholar 

  52. El Serag HB, Davila JA. Is fibrolamellar carcinoma different from hepatocellular carcinoma? A US population-based study. Hepatology. 2004;39:798–803.

    Article  PubMed  Google Scholar 

  53. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Qu W, Douglass EC, et al. Fibrolamellar hepatocellular carcinoma in children and adolescents. Cancer. 2003;97:2006–12.

    Article  PubMed  Google Scholar 

  54. Stipa F, Yoon SS, Liau KH, Fong Y, Jarnagin WR, D’Angelica M, et al. Outcome of patients with fibrolamellar hepatocellular carcinoma. Cancer. 2006;106:1331–8.

    Article  PubMed  Google Scholar 

  55. Craig JR, Peters RL, Edmondson HA, Omata M. Fibrolamellar carcinoma of the liver: a tumor of adolescents and young adults with distinctive clinico-pathologic features. Cancer. 1980;46:372–9.

    Article  PubMed  CAS  Google Scholar 

  56. Cheah PL, Looi LM, Lin HP, Yap SF. Childhood primary hepatocellular carcinoma and hepatitis B virus infection. Cancer. 1990;65:174–6.

    Article  PubMed  CAS  Google Scholar 

  57. Chang MH, Chen DS, Hsu HC, Hsu HY, Lee CY. Maternal transmission of hepatitis B virus in childhood hepatocellular carcinoma. Cancer. 1989;64:2377–80.

    Article  PubMed  CAS  Google Scholar 

  58. Kaposi-Novak P, Lee JS, Gomez-Quiroz L, Coulouarn C, Factor VM, Thorgeirsson SS. Met-regulated expression signature defines a subset of human hepatocellular carcinomas with poor prognosis and aggressive phenotype. J Clin Invest. 2006;116:1582–95.

    Article  PubMed  CAS  Google Scholar 

  59. Park WS, Dong SM, Kim SY, Na EY, Shin MS, Pi JH, et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999;59:307–10.

    PubMed  CAS  Google Scholar 

  60. Peng SY, Chou SP, Hsu HC. Association of downregulation of cyclin D1 and of overexpression of cyclin E with p53 mutation, high tumor grade and poor prognosis in hepatocellular carcinoma. J Hepatol. 1998;29:281–9.

    Article  PubMed  CAS  Google Scholar 

  61. Kim H, Lee MJ, Kim MR, Chung IP, Kim YM, Lee JY, et al. Expression of cyclin D1, cyclin E, cdk4 and loss of heterozygosity of 8p, 13q, 17p in hepatocellular carcinoma: comparison study of childhood and adult hepatocellular carcinoma. Liver. 2000;20:173–8.

    Article  PubMed  CAS  Google Scholar 

  62. Yu SB, Kim HY, Eo H, Won JK, Jung SE, Park KW, et al. Clinical characteristics and prognosis of pediatric hepatocellular carcinoma. World J Surg. 2006;30:43–50.

    Article  PubMed  Google Scholar 

  63. Bellani FF, Massimino M. Liver tumors in childhood: epidemiology and clinics. J Surg Oncol Suppl. 1993;3:119–21.

    Article  PubMed  CAS  Google Scholar 

  64. Czauderna P, Mackinlay G, Perilongo G, Brown J, Shafford E, Aronson D, et al. Hepatocellular carcinoma in children: results of the first prospective study of the International Society of Pediatric Oncology group. J Clin Oncol. 2002;20:2798–804.

    Article  PubMed  CAS  Google Scholar 

  65. Bruix J, Sherman M. Management of hepatocellular carcinoma. Hepatology. 2005;42:1208–36.

    Article  PubMed  Google Scholar 

  66. DeBaun MR, Tucker MA. Risk of cancer during the first four years of life in children from The Beckwith-Wiedemann Syndrome Registry. J Pediatr. 1998;132:398–400.

    Article  PubMed  CAS  Google Scholar 

  67. Katzenstein HM, Krailo MD, Malogolowkin MH, Ortega JA, Liu-Mares W, Douglass EC, et al. Hepatocellular carcinoma in children and adolescents: results from the Pediatric Oncology Group and the Children’s Cancer Group intergroup study. J Clin Oncol. 2002;20:2789–97.

    Article  PubMed  Google Scholar 

  68. Taketa K, Endo Y, Sekiya C, Tanikawa K, Koji T, Taga H, et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res. 1993;53:5419–23.

    PubMed  CAS  Google Scholar 

  69. Baumann U, Duhme V, Auth MK, McKiernan PJ, Holme E. Lectin-reactive alpha-fetoprotein in patients with tyrosinemia type I and hepatocellular carcinoma. J Pediatr Gastroenterol Nutr. 2006;43:77–82.

    Article  PubMed  CAS  Google Scholar 

  70. Saar B, Kellner-Weldon F. Radiological diagnosis of hepatocellular carcinoma. Liver Int. 2008;28:189–99.

    Article  PubMed  CAS  Google Scholar 

  71. Marrero JA, Hussain HK, Nghiem HV, Umar R, Fontana RJ, Lok AS. Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass. Liver Transplant. 2005;11:281–9.

    Article  Google Scholar 

  72. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693–9.

    Article  PubMed  CAS  Google Scholar 

  73. Shah SA, Cleary SP, Wei AC, Yang I, Taylor BR, Hemming AW, et al. Recurrence after liver resection for hepatocellular carcinoma: risk factors, treatment, and outcomes. Surgery. 2007;141:330–9.

    Article  PubMed  Google Scholar 

  74. Mazzaferro V, Llovet JM, Miceli R, Bhoori S, Schiavo M, Mariani L, et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009;10:35–43.

    Article  PubMed  Google Scholar 

  75. Roebuck DJ, Aronson D, Clapuyt P, Czauderna P, de Ville DG, Gauthier F, et al. PRETEXT: a revised staging system for primary malignant liver tumours of childhood developed by the SIOPEL group. Pediatr Radiol. 2007;37:123–32.

    Article  PubMed  Google Scholar 

  76. Brown J, Perilongo G, Shafford E, Keeling J, Pritchard J, Brock P, et al. Pretreatment prognostic factors for children with hepatoblastoma—results from the International Society of Paediatric Oncology (SIOP) study SIOPEL 1. Eur J Cancer. 2000;36:1418–25.

    Article  PubMed  CAS  Google Scholar 

  77. Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, et al. Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. J Am Med Assoc. 2010;304:2154–60.

    Article  CAS  Google Scholar 

  78. DeVita VTJ TSLaSAR. Cancer: principles & practice of oncology. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins; 2008.

    Google Scholar 

  79. Von Schweinitz D. International Society of Paediatric Oncology, SIOP XXXVII Annual Congress Meeting: Abstracts. Pediatr Blood Cancer 2005;45:371.

    Google Scholar 

  80. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010;11:1943–55.

    Article  PubMed  CAS  Google Scholar 

  81. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378–90.

    Article  PubMed  CAS  Google Scholar 

  82. Phase III Randomized Study of Sorafenib Tosylate With Versus Without Doxorubicin Hydrochloride in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma. http://www.cancer.gov/clinicaltrials/search/view?cdrid=659348&version=HealthProfessional&protocolsearchid=8987722. 2011. 31-3-2011 Jul 1;56(7):1013–8.

  83. Keir ST, Maris JM, Lock R, Kolb EA, Gorlick R, Carol H, et al. Initial testing (stage 1) of the multi-targeted kinase inhibitor sorafenib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2010;55:1126–33.

    Article  PubMed  Google Scholar 

  84. Otte JB. Should the selection of children with hepatocellular carcinoma be based on Milan criteria? Pediatr Transplant. 2008;12:1–3.

    Article  PubMed  Google Scholar 

  85. Beaunoyer M, Vanatta JM, Ogihara M, Strichartz D, Dahl G, Berquist WE, et al. Outcomes of transplantation in children with primary hepatic malignancy. Pediatr Transplant. 2007;11:655–60.

    Article  PubMed  Google Scholar 

  86. Ismail H, Broniszczak D, Kalicinski P, Markiewicz-Kijewska M, Teisseyre J, Stefanowicz M, et al. Liver transplantation in children with hepatocellular carcinoma. Do Milan criteria apply to pediatric patients? Pediatr Transplant. 2009;13:682–92.

    Article  PubMed  CAS  Google Scholar 

  87. Kosola S, Lauronen J, Sairanen H, Heikinheimo M, Jalanko H, Pakarinen M. High survival rates after liver transplantation for hepatoblastoma and hepatocellular carcinoma. Pediatr Transplant. 2010;14:646–50.

    Article  PubMed  Google Scholar 

  88. Gupta AA, Gerstle JT, Ng V, Wong A, Fecteau A, Malogolowkin MH et al. Critical review of controversial issues in the management of advanced pediatric liver tumors. Pediatr Blood Cancer. 2011;56(7):1013–8.

    Google Scholar 

  89. Austin MT, Leys CM, Feurer ID, Lovvorn III HN, O’Neill Jr JA, Pinson CW, et al. Liver transplantation for childhood hepatic malignancy: a review of the United Network for Organ Sharing (UNOS) database. J Pediatr Surg. 2006;41:182–6.

    Article  PubMed  Google Scholar 

  90. Otte JB, Meyers R. PLUTO first report. Pediatr Transplant. 2010;14:830–5.

    Article  PubMed  Google Scholar 

  91. Otte JB. Progress in the surgical treatment of malignant liver tumors in children. Cancer Treat Rev. 2010;36:360–71.

    Article  PubMed  Google Scholar 

  92. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734–9.

    Article  PubMed  Google Scholar 

  93. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164–71.

    Article  PubMed  CAS  Google Scholar 

  94. Kudo M. Radiofrequency ablation for hepatocellular carcinoma: updated review in 2010. Oncology. 2010;78 Suppl 1:113–24.

    Article  PubMed  Google Scholar 

  95. Lau WY, Lai EC. The current role of radiofrequency ablation in the management of hepatocellular carcinoma: a systematic review. Ann Surg. 2009;249:20–5.

    Article  PubMed  Google Scholar 

  96. Cho YK, Kim JK, Kim MY, Rhim H, Han JK. Systematic review of randomized trials for hepatocellular carcinoma treated with percutaneous ablation therapies. Hepatology. 2009;49:453–9.

    Article  PubMed  Google Scholar 

  97. Ye J, Shu Q, Li M, Jiang TA. Percutaneous radiofrequency ablation for treatment of hepatoblastoma recurrence. Pediatr Radiol. 2008;38:1021–3.

    Article  PubMed  Google Scholar 

  98. Hoffer FA, Daw NC, Xiong X, Anghelescu D, Krasin M, Yan X, et al. A phase 1/pilot study of radiofrequency ablation for the treatment of recurrent pediatric solid tumors. Cancer. 2009;115:1328–37.

    Article  PubMed  Google Scholar 

  99. Sasaki Y, Imaoka S, Ishiguro S, Nakano H, Kasugai H, Fujita M, et al. Clinical features of small hepatocellular carcinomas as assessed by histologic grades. Surgery. 1996;119:252–60.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada

    Christiane Sokollik MD & Simon C. Ling MBChB, MRCP

  2. Division of Hematology/Oncology, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada

    Abha Gupta MD, MSc, FRCPC

Authors
  1. Christiane Sokollik MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Abha Gupta MD, MSc, FRCPC
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Simon C. Ling MBChB, MRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Simon C. Ling MBChB, MRCP .

Editor information

Editors and Affiliations

  1. Medical Center, Center for Liver Disease, The University of Chicago, 5841 South Maryland Ave. MC 7120, Chicago, 60637, Illinois, USA

    Nancy Reau

  2. , Texas Liver Institute, University of Texas, 621 Camden St, #202, San Antonio, 78215, Texas, USA

    Fred Poordad

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media New York

About this chapter

Cite this chapter

Sokollik, C., Gupta, A., Ling, S.C. (2012). Hepatocellular Carcinoma in Children. In: Reau, N., Poordad, F. (eds) Primary Liver Cancer. Clinical Gastroenterology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-61779-863-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-61779-863-4_7

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-61779-862-7

  • Online ISBN: 978-1-61779-863-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation